Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics has secured a key regulatory win as the European Medicines Agency’s committee backed extending the indication for FeRACCRU to include adolescents, broadening its use for iron deficiency treatment in patients aged 12 and older. The decision follows completion of the agreed pediatric plan and positive Phase 3 data on ferric maltol’s efficacy and safety in children, strengthening the product’s pediatric profile alongside earlier U.S. approval.
Under its European licensing deal, Norgine holds FeRACCRU’s marketing authorisation and will commercialise the expanded indication, triggering a €500,000 milestone payment to Shield. The move deepens Shield’s penetration in the global iron deficiency market, enhances its competitive positioning for ferric maltol as a differentiated oral iron therapy, and supports its strategy of leveraging partners to grow non-U.S. revenues.
The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia with its ferric maltol product, marketed as ACCRUFeR in the U.S. and FeRACCRU in Europe and other territories. The company partners with regional licensees including Viatris in the U.S., Norgine in the EU, and other firms across Canada, Asia-Pacific, and China, with patent protection on ferric maltol extending into the mid-2030s.
Average Trading Volume: 1,903,149
Technical Sentiment Signal: Hold
Current Market Cap: £85.47M
Find detailed analytics on STX stock on TipRanks’ Stock Analysis page.